In the following subgroup analysis, we found that trials that used third‐generation CAR‐T cells or coadministration dual‐targeting CAR‐T therapy had a significantly higher rate of CRS (93%, 95% CI: 88%–96%, I2 = 0%) than studies that used second‐generation CAR‐T cells or tandem anti‐CD22‐CD19 constructs (88%, 95% CI: 78%–94%, I2 = 0%) (p < 0.01). The gene discussed is CD22; the disease is congenital rubella syndrome.